Fridrik M A, Hausmaninger H, Michlmayr G, Haidinger R, Seewann H L, Lehnert M
1st Department of Medicine, AöKh-Linz, Austria.
Hematol Oncol. 1991 Jul-Oct;9(4-5):209-15. doi: 10.1002/hon.2900090406.
A combination of two non-cross-resistant regimens, CEOP and IMVP-Dexa given every 4 weeks, three to six times according to response was tested in patients with untreated histological proven high and intermediate grade non-Hodgkin's lymphoma. To date eight Austrian centres entered 37 patients in this multicentre trial. Data are available from 33 patients, three were excluded, two because of pretreatment, one because of wrong histology. Twenty-five patients are evaluable for response, 21 had a complete and three a partial remission, two of them entered a complete remission after radiotherapy to residual disease, resulting in a complete remission rate of 92 per cent. Only one patient progressed during therapy. Until now three patients relapsed after achieving a remission. Observation time is 0.4-23.8 months, median 8.8 months. Toxicity was primarily hematologic with 53.3 per cent of patients having granulocyte nadirs below 0.5 x 10(9)/L and 3.3 per cent below 0.1 x 10(9)/L. Although 60 per cent of patients had infections, there was only one life-threatening infection in an AIDS patient. CEOP-IMVP-Dexa can be safely given even in smaller hematologic centres and is able to achieve a high rate of complete responses in patients with high and intermediate grade malignant non-Hodgkin's lymphomas.
在未经治疗的组织学确诊为高级别和中级别非霍奇金淋巴瘤患者中，测试了两种无交叉耐药方案（CEOP和IMVP-Dexa）联合使用的情况，每4周给药一次，根据反应情况给药三至六次。迄今为止，八个奥地利中心将37名患者纳入了这项多中心试验。现有33名患者的数据，3名患者被排除，2名因预处理原因，1名因组织学错误。25名患者可评估反应情况，21名完全缓解，3名部分缓解，其中2名在对残留病灶进行放射治疗后进入完全缓解，完全缓解率为92%。只有1名患者在治疗期间病情进展。到目前为止，3名患者在缓解后复发。观察时间为0.4 - 23.8个月，中位数为8.8个月。毒性主要是血液学方面的，53.3%的患者粒细胞最低点低于0.5×10⁹/L，3.3%低于0.1×10⁹/L。尽管60%的患者发生感染，但仅1名艾滋病患者发生了危及生命的感染。即使在较小的血液学中心，CEOP-IMVP-Dexa也能安全给药，并且能够在高级别和中级别恶性非霍奇金淋巴瘤患者中实现较高的完全缓解率。
